<header id=044203>
Published Date: 1997-11-12 18:50:00 EST
Subject: PRO> Ribavirin, availability (11)
Archive Number: 19971112.2284
</header>
<body id=044203>
RIBAVIRIN, AVAILABILITY (11)
****************************
A ProMED-mail post
See Also
Ribavirin, availability (06) 970428101529
Ribavirin, availability (10): RFI 971110222050
Date: Tue, 11 Nov 1997 16:58:01 -0700
From: Gregory Mertz <GMertz@salud.unm.edu>
Intravenous ribavirin is currently available in a placebo-controlled trial
for treatment of suspected hantavirus pulmonary syndrome at three study
centers in the US (University of New Mexico, Albuquerque, New Mexico;
University of Utah, Salt Lake City, Utah; and University of Alabama at
Birmingham) and at one site in Canada (University of Alberta, Edmonton,
Alberta). The trial is sponsored by the NIAID Collaborative Antiviral
Study Group and is coordinated through the University of Alabama at
Birmingham, Richard Whitley, MD, PI).
Referrals of potential study subjects with suspected hantavirus pulmonary
syndrome may be made by contacting investigators at any of the study sites
or by contacting Dr. Greg Mertz at 888-866-7256 [toll-free or at
505-272-2000. Potential investigators who may be interested in
establishing a study site should contact Dr. Mertz at the University of New
Mexico at 505-272-5666 or by e-mail at <gmertz@salud.unm.edu> or Dr. Rich
Whitley at UAB at 205-934-5316.
--
Gregory J. Mertz, M.D.
Professor and Chief
Division of Infectious Diseases
Department of Medicine
University of New Mexico
Albuquerque, New Mexico 87131
[Thanks to Dr. Mertz for information about this study in response to
ProMED-mail's request for information about the current availability of
ribavirin for life-threatening disease. - Mod.ES
......................................es
--
*##########################################################*
ProMED-mail makes every effort to verify the reports that
are posted, but the accuracy and completeness of the
information, and of any statements or opinions based
thereon, are not guaranteed. The reader assumes all risks in
using information posted or archived by ProMED-mail. ISID
and its associated service providers shall not be held
responsible for errors or omissions or held liable for any
damages incurred as a result of use or reliance upon posted
or archived material.
************************************************************
Visit ProMED-mail's web site at <http://www.promedmail.org>.
Send all items for posting to: promed@promedmail.org
(NOT to an individual moderator). If you do not give your
full name and affiliation, it may not be posted. Send
commands to subscribe/unsubscribe, get archives, help,
etc. to: majordomo@promedmail.org. For assistance from a
human being send mail to: owner-promed@promedmail.org.
############################################################
############################################################
</body>
